Electronic Health Record Data in Cancer Learning Health Systems: Challenges and Opportunities
Andrew R. Post, Zachary Burningham, Ahmad Halwani
Abstract
Article Tools REVIEW ARTICLES Special Series: Challenges and Downsides of IT in Cancer Care Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/CCI.21.00158 JCO Clinical Cancer Informatics no. 6 (2022) e2100158. Published online March 30, 2022. PMID: 35353547 Electronic Health Record Data in Cancer Learning Health Systems: Challenges and Opportunities Andrew R. Post , MD, PhD1,2xAndrew R. PostSearch for articles by this author; Zachary Burningham, MPH, PhD3xZachary BurninghamSearch for articles by this author; and Ahmad S. Halwani , MD4xAhmad S. HalwaniSearch for articles by this author Show More 1Research Informatics Shared Resource, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT2Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, UT3Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT4Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT https://doi.org/10.1200/CCI.21.00158 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyCONTEXTKey ObjectiveTo provide a narrative review of challenges and opportunities with electronic health record (EHR) data, including interoperability and integration with other data sources, impacts on cancer research and cancer care, and promising directions for next-generation EHR technologies.Knowledge GeneratedAlthough federal EHR technology investments had disappointing results, they were necessary to start digitizing the nation's health care data and set the stage for a promising future. An architecture focused on application programming interfaces and data standards provides a flexible approach that is highly likely to accommodate precision oncology and enable a rapid learning health system.RelevanceNew EHR technologies promise to support all levels of the data-information-knowledge-wisdom pyramid through efficient capture of clinical and molecular data on individuals, visualization of longitudinal context of care (information), use of real-world data to enable new and rapid modes of cancer research (knowledge), and clinical decision support driven by near real-time analyses of patient populations (wisdom).SUPPORTSupported by the National Cancer Institute of the National Institutes of Health under Award No. P30CA042014.AUTHOR CONTRIBUTIONSConception and design: All authorsFinancial support: Andrew R. PostAdministrative support: Andrew R. PostProvision of study material or patients: Andrew R. PostCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Zachary BurninghamResearch Funding: AbbVie, Genentech/Roche, PharmacyclicsAhmad S. HalwaniResearch Funding: Bristol Myers Squibb (Inst), Kyowa Hakko Kirin (Inst), Roche/Genentech (Inst), AbbVie/Genentech (Inst), AbbVie (Inst), Immune Design (Inst), miRagen (Inst), Amgen (Inst), Seattle Genetics (Inst), Genentech (Inst), Takeda (Inst), Pharmacyclics (Inst), Bayer (Inst)Travel, Accommodations, Expenses: Pharmacyclics, AbbVie, Seattle Genetics, Immune DesignNo other potential conflicts of interest were reported.